{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:31:20Z","timestamp":1793215880875,"version":"4.5.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T00:00:00Z","timestamp":1332115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Denosumab has been shown to reduce the incidence of vertebral, nonvertebral, and hip fractures. The aim of the current study was to determine whether the antifracture efficacy of denosumab was dependent on baseline fracture probability assessed by FRAX. The primary data of the phase 3 FREEDOM study of the effects of denosumab in women with postmenopausal osteoporosis were used to compute country-specific probabilities using the FRAX tool (version 3.2). The outcome variable comprised all clinical osteoporotic fractures (including clinical vertebral fractures). Interactions between fracture probability and efficacy were explored by Poisson regression. At baseline, the median 10-year probability of a major osteoporotic fracture (with bone mineral density) was approximately 15% and for hip fracture was approximately 5% in both groups. In the simplest model adjusted for age and fracture probability, treatment with denosumab over 3 years was associated with a 32% (95% confidence interval [CI] 20% to 42%) decrease in clinical osteoporotic fractures. Denosumab reduced fracture risk to a greater extent in those at moderate to high risk. For example, at 10% probability, denosumab decreased fracture risk by 11% (p\u2009=\u20090.629), whereas at 30% probability (90th percentile of study population) the reduction was 50% (p\u2009=\u20090.001). The reduction in fracture was independent of prior fracture, parental history of hip fracture, or secondary causes of osteoporosis. A low body mass index (BMI) was associated with greater efficacy. Denosumab significantly decreased the risk of clinical osteoporotic fractures in postmenopausal women. Overall, the efficacy of denosumab was greater in those at moderate to high risk of fracture as assessed by FRAX. \u00a9 2012 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1606","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T18:42:54Z","timestamp":1332182574000},"page":"1480-1486","source":"Crossref","is-referenced-by-count":125,"title":["Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX"],"prefix":"10.1093","volume":"27","author":[{"given":"Eugene V","family":"McCloskey","sequence":"first","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Johansson","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Oden","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Austin","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Siris","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Wang","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Michael","family":"Lewiecki","sequence":"additional","affiliation":[{"name":"New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Lorenc","sequence":"additional","affiliation":[{"name":"The Children's Memorial Health Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Libanati","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A","family":"Kanis","sequence":"additional","affiliation":[{"name":"WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,3,19]]},"reference":[{"issue":"12","key":"2024020318272363900_bib1","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"8","key":"2024020318272363900_bib2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med."},{"issue":"8","key":"2024020318272363900_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020318272363900_bib4","author":"Kanis JA on behalf of the WHO Scientific Group"},{"issue":"8","key":"2024020318272363900_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","article-title":"The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women","volume":"18","author":"Kanis","year":"2007","journal-title":"Osteoporos Int."},{"issue":"6","key":"2024020318272363900_bib6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","article-title":"Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX","volume":"44","author":"Kanis","year":"2009","journal-title":"Bone."},{"issue":"5","key":"2024020318272363900_bib7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","article-title":"Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study","volume":"20","author":"McCloskey","year":"2009","journal-title":"Osteoporos Int."},{"issue":"4","key":"2024020318272363900_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bone.2010.06.009","article-title":"A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX","volume":"47","author":"Kanis","year":"2010","journal-title":"Bone."},{"issue":"8","key":"2024020318272363900_bib9","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00198-010-1474-0","article-title":"A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX","volume":"22","author":"Kanis","year":"2011","journal-title":"Osteoporos Int."},{"issue":"9","key":"2024020318272363900_bib10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020318272363900_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-009-1034-7","article-title":"The potential impact of new National Osteoporosis Foundation guidance on treatment patterns","volume":"21","author":"Dawson-Hughes","year":"2010","journal-title":"Osteoporos Int."},{"key":"2024020318272363900_bib12","first-page":"131","volume-title":"Statistical methods in cancer research","author":"Breslow","year":"1987"},{"issue":"6","key":"2024020318272363900_bib13","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2024020318272363900_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00198-011-1846-0","article-title":"Pitfalls in the external validation of FRAX","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int."},{"issue":"5","key":"2024020318272363900_bib15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-007-0493-y","article-title":"Effects of risedronate on fracture risk in postmenopausal women with osteopenia","volume":"19","author":"Siris","year":"2008","journal-title":"Osteoporos Int."},{"issue":"2","key":"2024020318272363900_bib16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF03324588","article-title":"Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data","volume":"17","author":"Adachi","year":"2005","journal-title":"Aging Clin Exp Res."},{"issue":"9","key":"2024020318272363900_bib17","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2024020318272363900_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","article-title":"Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors","volume":"21","author":"Roux","year":"2006","journal-title":"J Bone Miner Res."},{"issue":"1","key":"2024020318272363900_bib19","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J Bone Miner Res."},{"issue":"2","key":"2024020318272363900_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone."},{"issue":"24","key":"2024020318272363900_bib21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"issue":"7","key":"2024020318272363900_bib22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1359\/jbmr.1998.13.7.1167","article-title":"Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group","volume":"13","author":"Stone","year":"1998","journal-title":"J Bone Miner Res."},{"issue":"7","key":"2024020318272363900_bib23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00198-009-1077-9","article-title":"Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial","volume":"21","author":"Eastell","year":"2010","journal-title":"Osteoporos Int."},{"issue":"2","key":"2024020318272363900_bib24","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.bone.2010.05.020","article-title":"FRAX and its applications in health economics\u2014cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example","volume":"47","author":"Strom","year":"2010","journal-title":"Bone."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1606","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/7\/1480\/56560474\/1606_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/27\/7\/1480\/56560474\/1606_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:46:27Z","timestamp":1710341187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/27\/7\/1480-1486\/7598291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,19]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,3,19]]},"published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1606","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,7,1]]},"published":{"date-parts":[[2012,3,19]]}}}